Newly identified mechanisms in B-cell non-hodgkin lymphomas uncovered by next-generation sequencing

Seminars in Hematology

Volumn 50, Issue 4, 2013, Pages 303-313

  Morin, Ryan D ^a,b   Gascoyne, Randy D ^b,c  

^a SIMON FRASER UNIVERSITY   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH RECEPTOR;

ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; EPIGENETICS; GENE EXPRESSION PROFILING; GENE FUSION; GENE MUTATION; GENE SEQUENCE; GENETIC DISORDER; GENETIC HETEROGENEITY; GENETIC PROCEDURES; GERMINAL CENTER; HUMAN; LARGE CELL LYMPHOMA; MULTIPLE MYELOMA; NEXT GENERATION SEQUENCING; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; WALDENSTROEM MACROGLOBULINEMIA;

HUMANS; LYMPHOMA, B-CELL; MUTATION; ONCOGENES; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84887535855     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.09.004     Document Type: Article

References (56)

1. Dave S., Fu K., Wright G.W., et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006, 354:2431-2442.
2. Rosenwald A., Wright G., Leroy K., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003, 198:851-862.
3. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
4. Morin R., Bainbridge M., Fejes A., et al. Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing. Biotechniques 2008, 45:81-94.
5. Marioni J.C., Mason C.E., Mane S.M., et al. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res 2008, 18:1509-1517.
6. Morin R.D., Johnson N.A., Severson T.M., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010, 42:181-185.
7. Ngo V.N., Young R.M., Schmitz R., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470:115-119.
8. Greenman C., Stephens P., Smith R., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
9. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
10. Morin R.D., Mendez-Lago M., Mungall A.J., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303.
11. Kridel R., Meissner B., Rogic S., et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012, 119:1963-1971.
12. Lohr J.G., Stojanov P., Lawrence M.S., et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012, 109:3879-3884.
13. Love C., Sun Z., Jima D., et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012, 44:1321-1325.
14. Zhang J., Grubor V., Love C.L., et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2013, 110:1398-1403.
15. Shaffer A.L., Young R.M., Staudt L.M. Pathogenesis of human B Cell lymphomas. Annu Rev Immunol 2012, 30:565-610.
16. Ngo V.N., Davis R.E., Lamy L., et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006, 441:106-110.
17. Pasqualucci L., Compagno M., Houldsworth J., et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006, 203:311-317.
18. Rui L., Schmitz R., Ceribelli M., et al. Malignant pirates of the immune system. Nat Immunol 2011, 12:933-940.
19. Lenz G., Staudt L.M. Aggressive lymphomas. N Engl J Med 2010, 362:1417-1429.
20. Lenz G., Davis R.E., Ngo V.N., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319:1676-1679.
21. Davis R.E., Ngo V.N., Lenz G., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
22. Puente X.S., Pinyol M., Quesada V., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
23. Chapman M.A., Lawrence M.S., Keats J.J., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471:467-472.
24. Quesada V., Conde L., Villamor N., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2011, 44:47-52.
25. Treon S.P., Xu L., Yang G., et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 2012, 367:826-833.
26. Cheung K.-J.J., Johnson N.A., Affleck J.G., et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res 2010, 70:9166-9174.
27. Pasqualucci L., Dominguez-Sola D., Chiarenza A., et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471:189-195.
28. Pasqualucci L., Trifonov V., Fabbri G., et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011, 43:830-837.
29. Pasqualucci L., Neumeister P., Goossens T., et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001, 412:341-346.
30. Khodabakhshi A.H., Morin R.D., Fejes A.P., et al. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget 2012, 3:1308-1319.
31. Morin R.D., Mungall K., Pleasance E., et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole genome sequencing. Blood 2013, 122:1256-1265.
32. Trinh D.L., Scott D.W., Morin R.D., et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood 2013, 121:3666-3674.
33. Green J.A., Suzuki K., Cho B., et al. The sphingosine 1-phosphate receptor S1P2 maintains the homeostasis of germinal center B cells and promotes niche confinement. Nat Immunol 2011, 12:672-680.
34. Cattoretti G., Mandelbaum J., Lee N., et al. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res 2009, 69:8686-8692.
35. Li Z., Dong X., Wang Z., et al. Regulation of PTEN by Rho small GTPases. Nat Cell Biol 2005, 7:399-404.
36. Richter J., Schlesner M., Hoffmann S., et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012, 44:1316-1320.
37. Schmitz R., Young R.M., Ceribelli M., et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012, 490:116-120.
38. Scott D.W., Mungall K.L., Ben-Neriah S., et al. TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. Blood 2012, 119:4949-4952.
39. Vasmatzis G., Johnson S.H., Ra K.n.u.d.s.o.n., et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 2012, 120:2280-2289.
40. Dave S.S., Wright G., Tan B., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004, 351:2159-2169.
41. Lenz G., Wright G., Dave S.S., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359:2313-2323.
42. Steidl C., Lee T., Shah S.P., et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010, 362:875-885.
43. Steidl C., Shah S.P., Woolcock B.W., et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011, 471:377-381.
44. Steidl C., Gascoyne R.D. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011, 118:2659-2669.
45. Challa-Malladi M., Lieu Y.K., Califano O., et al. Combined genetic inactivation of β2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011, 20:728-740.
46. Shaknovich R., Melnick A. Epigenetics and B-cell lymphoma. Curr Opin Hematol 2011, 18:293-299.
47. Ying C.Y., Dominguez-Sola D., Fabi M., et al. MEF2B mutations lead to de-regulated expression of the BCL6 oncogene in diffuse large B-cell lymphoma and follicular lymphoma. Blood 2012, 120:1284.
48. Mendez-Lago M., Morin R.D., Mungall A.J., et al. Mutations in MLL2 and MEF2B genes in follicular lymphoma and diffuse large B-cell lymphoma. Blood 2010, 116:473.
49. Taylor K.H., Briley A., Wang Z., et al. Aberrant epigenetic gene regulation in lymphoid malignancies. Semin Hematol 2013, 50:38-47.
50. Weng A.P., Ferrando A.A., Lee W., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269-271.
51. Kiel M.J., Velusamy T., Betz B.L., et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 2012, 209:1553-1565.
52. Rossi D., Trifonov V., Fangazio M., et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 2012, 209:1537-1551.
53. Meissner B., Kridel R., Lim R.S., et al. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood 2013, 121:3161-3164.
54. Forbes S.A., Bindal N., Bamford S., et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011, 39:D945-D950.
55. Yap D.B., Chu J., Berg T., et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011, 117:2451-2459.
56. Sneeringer C.J., Scott M.P., Kuntz K.W., et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A 2010, 107:20980-20985.